Clinical Trial Update: Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing reactogenicity, safety, and immunogenicity of the QazCoVac-P COVID-19 vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov Infection

Drugs mentioned

• QazCoVac-P

Snippet

Sponsor: Research Institute for Biological Safety Problems | Conditions: Covid19, SARS-CoV Infection | Phase 1, Phase 2 | Status: COMPLETED